Rudolf A. de Boer

发表

Effects of Dapagliflozin in Patients in Asia

P. Jhund, M. Vaduganathan, M. Kitakaze, 2023, JACC: Asia.

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, JAMA cardiology.

Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.

S. Batkai, O. Vardeny, S. Rump, 2024, European journal of heart failure.

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2024, European journal of heart failure.

Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, Journal of cardiac failure.

Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial

P. Jhund, M. Vaduganathan, D. Lindholm, 2023, European journal of heart failure.

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, F. Martinez, 2024, European journal of heart failure.

Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data

E. Bachus, Jason A. Davis, Scott D. Solomon, 2024, European journal of heart failure.

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure

P. Ponikowski, G. Filippatos, L. Lund, 2019, European journal of heart failure.

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction

Akshay S. Desai, D. DeMets, P. Ponikowski, 2020, Circulation.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Akshay S. Desai, D. DeMets, P. Ponikowski, 2019, The New England journal of medicine.

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

Sanjiv J. Shah, D. DeMets, S. Solomon, 2021, European journal of heart failure.

Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, NEJM evidence.

World Heart Federation Roadmap for Heart Failure.

K. Sliwa, I. Piña, C. Yancy, 2019, Global heart.

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Sanjiv J. Shah, D. DeMets, S. Solomon, 2022, JACC. Heart failure.

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

Akshay S. Desai, D. DeMets, P. Ponikowski, 2019, European journal of heart failure.